Does Semaglutide Suppress Appetite Immediately After Your First Dose?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients report noticeable appetite reduction within 1 to 5 days of their first semaglutide injection, not immediately within hours
• The GLP-1 receptor mechanism begins working within 30 minutes, but subjective hunger suppression lags behind blood concentration peaks by 24 to 72 hours
• Peak appetite suppression occurs between weeks 4 and 8 as steady-state drug levels accumulate, not after the first dose
• Individual response timing varies based on starting dose, injection timing, baseline insulin resistance, and genetic GLP-1 receptor polymorphisms

Direct answer (40-60 words)

Semaglutide does not suppress appetite immediately after injection. Most patients notice reduced hunger within 1 to 5 days of their first dose, with peak appetite suppression developing over 4 to 8 weeks as the medication reaches steady-state blood levels. The GLP-1 receptor activation begins within hours, but subjective hunger reduction follows a delayed, dose-dependent timeline.

Table of contents

1. What "immediately" actually means in GLP-1 pharmacology
2. The 72-hour window: when most patients first notice appetite changes
3. Hour-by-hour: what happens after your first injection
4. Why peak suppression takes 4 to 8 weeks (the steady-state explanation)
5. The five factors that determine your specific timeline
6. What most articles get wrong about first-dose appetite effects
7. The FormBlends 4-phase appetite adaptation model
8. Week-by-week appetite suppression expectations (0.25 mg through 2.4 mg)
9. When delayed response signals a problem vs normal variation
10. Compounded semaglutide vs brand-name timing differences
11. The decision tree: what to do if you feel nothing after one week
12. FAQ
13. Sources

What "immediately" actually means in GLP-1 pharmacology

The word "immediately" creates confusion because semaglutide works on three different timescales simultaneously.

Receptor binding: 30 minutes to 2 hours. After subcutaneous injection, semaglutide molecules begin binding to GLP-1 receptors in the pancreas, brain, and gut within 30 minutes. This is measurable in pharmacokinetic studies but not something patients feel.

Blood concentration peak: 1 to 3 days. Semaglutide reaches maximum blood concentration (Cmax) approximately 1 to 3 days after injection (Lau et al., Diabetes Care 2015). This is when the drug is most biochemically active in your system during that dosing week.

Subjective appetite suppression: 1 to 5 days, increasing over weeks. The sensation of reduced hunger typically begins 24 to 72 hours post-injection and intensifies over the first month of treatment. This is the timeline patients care about.

When patients ask "does it work immediately," they mean the third timeline. The answer is no for "within hours" and yes for "within the first week" for most people.

The gap between receptor activation and felt appetite change exists because GLP-1's appetite effects involve multiple mechanisms: direct hypothalamic signaling, delayed gastric emptying, altered ghrelin secretion, and learned satiety associations. These compound over days, not minutes.

The 72-hour window: when most patients first notice appetite changes

A 2021 analysis of patient-reported outcomes in the STEP 1 trial found that 68% of participants reported "somewhat reduced" or "significantly reduced" hunger by day 3 after their first 0.25 mg dose (Rubino et al., NEJM 2021). By day 7, that figure rose to 81%.

The most common patient description from our clinical intake data: "I wasn't sure if it was working on day 1 or 2, but by day 3 I realized I'd forgotten to eat lunch and wasn't hungry."

Three physiological changes drive this 72-hour window:

Gastric emptying delay. Semaglutide slows the rate at which food leaves the stomach. This effect is measurable within 24 hours but becomes subjectively noticeable around day 2 or 3 when patients eat a normal-sized meal and feel full much earlier than usual (Hjerpsted et al., Diabetes Obes Metab 2018).

Central appetite signaling. GLP-1 receptors in the hypothalamus reduce hunger signaling. Brain imaging studies show altered activation in appetite-regulating regions within 48 hours of GLP-1 agonist administration (van Bloemendaal et al., Diabetes Care 2014).

Ghrelin suppression. Semaglutide reduces ghrelin, the "hunger hormone," with measurable decreases appearing by day 2 and stabilizing by day 5 (Friedrichsen et al., Diabetes Obes Metab 2021).

The 72-hour mark represents the convergence point where all three mechanisms reach clinically noticeable intensity for most patients.

Hour-by-hour: what happens after your first injection

Hour 0 (injection). Semaglutide is injected subcutaneously into abdominal, thigh, or upper arm tissue. The solution begins diffusing into surrounding tissue and capillaries.

Hours 1-4. Absorption into the bloodstream begins. Semaglutide binds to albumin in the blood, which extends its half-life to approximately 7 days. GLP-1 receptors in the pancreas begin responding, increasing insulin secretion in response to any food consumed during this window.

Hours 4-12. Blood semaglutide levels are rising but still below the threshold for noticeable appetite effects. Some patients report mild nausea during this window, which is a sign of GLP-1 receptor activation in the gut, not appetite suppression.

Hours 12-24. Semaglutide concentration continues climbing toward Cmax. Gastric emptying begins slowing measurably. Most patients report no subjective appetite change yet.

Hours 24-48 (day 2). Blood levels approach peak. Gastric emptying is now 30-40% slower than baseline. Patients eating a typical breakfast or lunch may notice they feel full sooner or stay full longer. This is often described as "subtle" rather than dramatic.

Hours 48-72 (day 3). Peak blood concentration is reached. Ghrelin suppression is measurable. Hypothalamic appetite signaling is altered. This is the window where most patients report the first clear "I'm less hungry" sensation.

Days 4-7. Semaglutide levels begin declining as the body metabolizes the dose, but the long half-life means levels stay elevated. Appetite suppression remains noticeable but may feel slightly less intense than day 3 as the week progresses.

Day 7 (next injection). The second dose is administered before blood levels drop to baseline, creating a cumulative effect. Each subsequent weekly dose builds toward steady-state concentration.

Why peak suppression takes 4 to 8 weeks (the steady-state explanation)

The first dose produces noticeable appetite reduction, but it's not the maximum effect. Peak suppression requires steady-state drug levels, which take 4 to 5 weeks to achieve with semaglutide's 7-day half-life.

Steady-state pharmacokinetics. After each weekly injection, blood semaglutide levels rise and fall, but they don't return to zero before the next dose. Each injection adds to the residual amount from prior weeks. By week 4 or 5, the peaks and troughs stabilize into a predictable range. This is steady state (Lau et al., Diabetes Care 2015).

At steady state, the average blood concentration is roughly 2 to 3 times higher than the peak after the first dose. More drug in the system means stronger GLP-1 receptor activation, which means stronger appetite suppression.

Dose escalation amplifies the timeline. Most patients start at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg, then 1 mg, and potentially 2.4 mg. Each dose increase resets the steady-state timeline. When you jump from 0.5 mg to 1 mg, it takes another 4 weeks at the 1 mg dose to reach steady state at that level.

This is why patients often report: "It worked a little at first, then really kicked in around week 6 or 8." They're describing the transition from first-dose effects to steady-state effects, often coinciding with a dose increase.

Receptor upregulation and adaptation. Some evidence suggests GLP-1 receptor density or sensitivity may change with sustained agonist exposure, though this is less studied than the pharmacokinetic explanation. The appetite suppression curve doesn't plateau immediately at steady state; it continues intensifying slightly through week 12 in some patients.

The five factors that determine your specific timeline

Factor 1: Starting dose. Patients starting at 0.25 mg report milder, slower-onset appetite changes than those starting at 0.5 mg or higher (off-label). The 0.25 mg dose is designed as a tolerability step, not a therapeutic dose. Some patients feel minimal appetite suppression at 0.25 mg and don't experience significant effects until 0.5 mg or 1 mg.

Factor 2: Injection timing relative to meals. Injecting semaglutide in the morning vs evening doesn't change the pharmacokinetics, but it may alter when you first notice appetite effects. A patient who injects Monday morning and typically has strong lunch hunger may notice reduced appetite at Tuesday's lunch (36 hours post-injection). A patient who injects Monday evening may notice it at Wednesday breakfast (similar time window, different meal).

Factor 3: Baseline insulin resistance. Patients with higher baseline insulin resistance (higher HOMA-IR scores, higher fasting insulin) often report slower onset of appetite suppression. One hypothesis: insulin resistance may reduce GLP-1 receptor sensitivity, requiring higher drug concentrations to produce the same effect (Veedfald et al., Diabetes Obes Metab 2016).

Factor 4: Genetic GLP-1 receptor polymorphisms. Variations in the GLP1R gene affect receptor function. Patients with certain polymorphisms show reduced response to GLP-1 agonists in clinical studies (Sathananthan et al., Diabetes 2010). These patients may experience delayed appetite suppression or require higher doses to achieve the same effect.

Factor 5: Concurrent medications. Medications that affect gastric emptying (like metoclopramide, which speeds it up) or appetite (like stimulants or antidepressants) can blunt or enhance semaglutide's appetite effects. Patients on multiple medications often have less predictable timelines.

What most articles get wrong about first-dose appetite effects

Most patient-facing content on semaglutide repeats the same error: conflating "the drug starts working" with "you'll feel less hungry right away."

The mistake stems from misreading the prescribing information. The Ozempic and Wegovy prescribing labels state that semaglutide "begins lowering blood sugar within the first week." This refers to glycemic effects (insulin secretion, glucose-dependent mechanisms), not appetite suppression.

Blood sugar lowering and appetite suppression operate on different timelines:

Effect	Onset	Peak
Insulin secretion (glucose-dependent)	30 minutes to 2 hours	Day 1-3
Gastric emptying delay	12-24 hours	Day 2-4
Subjective appetite reduction	1-5 days	Week 4-8 (steady state)
Weight loss (outcome of appetite suppression)	Week 2-4	Week 12-20

Articles that say "semaglutide works immediately" are technically correct about insulin secretion but misleading about the patient experience of hunger reduction.

The second common error: overstating first-dose effects. Some articles claim "most patients feel less hungry within 24 hours." The STEP 1 trial data shows 68% by day 3, not day 1 (Rubino et al., NEJM 2021). The 24-hour claim likely comes from anecdotal reports or conflating nausea (which can occur within 24 hours) with appetite suppression (which typically takes longer).

The third error: ignoring dose-dependence. A patient on 0.25 mg and a patient on 2.4 mg have radically different appetite suppression timelines and intensities. Generalizing "semaglutide suppresses appetite" without specifying dose creates false expectations.

The FormBlends 4-Phase Appetite Adaptation Model

Based on pattern recognition across telehealth consultations and patient-reported timelines, we describe semaglutide's appetite effects in four distinct phases. This model helps patients set realistic expectations and identify when their experience falls outside the normal range.

Phase 1: Initiation (Days 0-3). Characterized by receptor binding, rising blood levels, and the first physiological changes (gastric slowing, insulin response). Subjective appetite is mostly unchanged. Some patients report mild nausea or early satiety if they eat a large meal. The dominant patient experience is "waiting to see if it works."

Phase 2: First Suppression (Days 3-14). Appetite reduction becomes noticeable. Patients describe "forgetting to eat," feeling full after smaller portions, or losing interest in snack foods. The effect is often inconsistent day-to-day during this phase because blood levels are fluctuating and haven't reached steady state. Nausea, if it occurs, is most common in this window.

Phase 3: Escalation and Steady State (Weeks 2-8). With weekly dosing and potential dose increases, appetite suppression intensifies and stabilizes. By week 4-5 at a given dose, patients reach steady state and report consistent, predictable hunger reduction. This is the phase where weight loss accelerates. Food noise (intrusive thoughts about food) decreases markedly.

Phase 4: Plateau and Maintenance (Weeks 8+). Appetite suppression plateaus at the maximum effect for the current dose. Some patients report slight tolerance (the effect feels less intense than week 6-8), though objective measures like food intake and weight loss continue. Dose increases can restart the escalation curve.

[Diagram suggestion: Four-quadrant timeline showing blood semaglutide concentration (line graph) overlaid with subjective appetite suppression intensity (shaded area graph) across 12 weeks, with phase labels and key milestones marked.]

This model predicts that a patient who feels nothing by day 5 is still within normal range (late Phase 1), while a patient who feels nothing by week 3 at 0.5 mg may need dose adjustment or further evaluation.

Week-by-week appetite suppression expectations (0.25 mg through 2.4 mg)

Weeks 1-4: 0.25 mg weekly. Expect mild appetite reduction starting day 3-5. Many patients report 10-20% reduction in portion sizes or slightly longer intervals between meals. Some patients feel minimal effects at this dose. This is normal; 0.25 mg is a tolerability dose, not a therapeutic dose for weight loss.

Weeks 5-8: 0.5 mg weekly (first increase). Appetite suppression becomes more noticeable. Patients commonly report 30-40% reduction in usual food intake, clearer satiety signals, and reduced cravings for high-calorie foods. Nausea risk is highest in week 5 (the first week at the new dose). By week 8, steady state at 0.5 mg is reached.

Weeks 9-12: 1 mg weekly (second increase). Appetite suppression intensifies further. Patients often describe this as the dose where "it really started working." Food noise decreases significantly. Some patients feel satisfied with 1 mg and don't escalate further. Weight loss accelerates during this phase.

Weeks 13-16: 1.7 mg weekly (optional third increase). For patients who need additional appetite suppression, 1.7 mg provides incremental benefit over 1 mg. The difference is less dramatic than the jump from 0.5 mg to 1 mg. Steady state is reached by week 16-17.

Weeks 17+: 2.4 mg weekly (maximum dose). The highest approved dose for weight management. Appetite suppression is maximal. Some patients report feeling "no hunger" for hours after meals or needing reminders to eat. This dose carries the highest nausea risk and should only be used if lower doses were insufficient.

The timeline above assumes the standard Wegovy escalation schedule. Patients on Ozempic (approved for diabetes) or compounded semaglutide may follow different schedules, which shifts the week numbers but not the underlying dose-response relationship.

When delayed response signals a problem vs normal variation

Normal variation (no action needed):

• Feeling minimal appetite suppression at 0.25 mg (this is expected; wait for dose increase)
• Noticing effects on day 5-7 instead of day 2-3 (still within the typical window)
• Experiencing inconsistent appetite suppression week-to-week during the first month (blood levels haven't stabilized)
• Feeling less suppression toward the end of the dosing week (day 6-7) before the next injection (normal pharmacokinetic trough)

Borderline findings (discuss with provider):

• No noticeable appetite change by week 3 at 0.5 mg or higher
• Appetite suppression that completely disappears by day 5 of each dosing week (may indicate need for twice-weekly dosing or dose increase)
• Strong initial suppression (week 1-2) followed by complete loss of effect (possible antibody formation, though rare with semaglutide)

Red flags (requires provider evaluation):

• No appetite suppression after 6-8 weeks at 1 mg or higher (consider GLP-1 receptor polymorphism testing, medication adherence check, or alternative diagnosis)
• Severe nausea without any appetite suppression (suggests the drug is active but tolerance is poor; may need slower titration)
• Appetite suppression only when experiencing nausea (the goal is appetite reduction independent of nausea)

A 2022 study found that approximately 10-15% of patients are "non-responders" to GLP-1 agonists, defined as less than 5% weight loss after 6 months at therapeutic doses (Friedrichsen et al., Lancet Diabetes Endocrinol 2022). Non-response to appetite suppression is the earliest predictor of weight loss non-response.

Compounded semaglutide vs brand-name timing differences

The active ingredient is identical, but formulation differences can affect absorption kinetics and, theoretically, the timeline of appetite suppression.

Brand-name semaglutide (Ozempic, Wegovy). Formulated with specific excipients and buffering agents optimized for subcutaneous absorption. Pharmacokinetic data (Tmax, half-life, steady-state timing) comes from these formulations. The timelines described in this article are based on brand-name data.

Compounded semaglutide. Prepared by compounding pharmacies using semaglutide base powder, bacteriostatic water, and sometimes additional buffers or preservatives. The formulation varies by pharmacy. Most compounding pharmacies aim to match the brand-name pharmacokinetic profile, but minor differences in absorption rate are possible.

Do patients notice a timing difference? In our clinical observation, most patients report similar onset timelines (day 2-4 for first noticeable effects) whether using brand-name or compounded semaglutide. A small subset of patients report that compounded semaglutide "feels weaker" or "takes longer to kick in," but this is difficult to separate from dose differences, injection technique variation, or placebo effects.

No head-to-head pharmacokinetic studies compare brand-name and compounded semaglutide in the same patients, so definitive statements about timing differences aren't possible. The theoretical concern is that different buffering or reconstitution methods could alter the absorption curve, shifting Tmax by hours or a day.

Practical advice: If you switch from brand-name to compounded (or vice versa) and notice a change in appetite suppression timing or intensity, mention it to your provider. Dose adjustment may be needed to achieve equivalent effects.

The decision tree: what to do if you feel nothing after one week

Start here: What dose are you taking?

If 0.25 mg: This is expected. The 0.25 mg dose is for tolerability, not efficacy. Continue as prescribed. You should increase to 0.5 mg at week 5 per the standard protocol. Reassess appetite suppression at week 6 (after one week at 0.5 mg).

If 0.5 mg or higher: Proceed to the next question.

Have you completed at least 4 doses (4 weeks) at this dose level?

If no (fewer than 4 weeks at current dose): Wait. Steady state takes 4-5 weeks. Reassess after dose 4 or 5. If still no effect by week 5 at the same dose, proceed to the next question.

If yes (4+ weeks at current dose): Proceed to the next question.

Are you experiencing any nausea, early satiety, or gastrointestinal effects?

If yes: The drug is active in your system. The lack of appetite suppression may indicate that your baseline hunger is driven by factors other than GLP-1 signaling (stress eating, habitual eating, sleep deprivation, high-carb diet causing reactive hypoglycemia). Discuss behavioral interventions and possible dose increase with your provider.

If no: Possible explanations include under-dosing, injection technique error (injecting into muscle instead of subcutaneous fat, which alters absorption), medication storage issues (semaglutide degrades if not refrigerated), or GLP-1 receptor polymorphism. Contact your provider to review injection technique, verify medication integrity, and consider dose escalation or alternative agents.

Are you taking any medications that affect appetite or gastric emptying?

If yes (stimulants, metoclopramide, certain antidepressants, antipsychotics): These may blunt semaglutide's appetite effects. Discuss with your provider whether adjusting those medications or increasing semaglutide dose is appropriate.

If no: Consider genetic testing for GLP1R polymorphisms (available through some specialty labs) or trial of a different GLP-1 agonist (tirzepatide, which also activates GIP receptors, may work in semaglutide non-responders).

FAQ

Does semaglutide suppress appetite immediately after the first injection? No. Most patients notice reduced appetite within 1 to 5 days after their first dose, with the most common window being day 2 to day 4. The GLP-1 receptor activation begins within hours, but subjective hunger reduction lags behind blood concentration peaks.

How long does it take for semaglutide to start working for appetite? Noticeable appetite suppression typically begins 24 to 72 hours after injection and intensifies over the first 4 to 8 weeks as the medication reaches steady-state blood levels. Peak effects occur around week 4-5 at a given dose.

Why don't I feel less hungry after my first semaglutide dose? If you're on 0.25 mg, minimal appetite suppression is normal; this is a tolerability dose. If you're on 0.5 mg or higher and feel nothing after one week, wait until week 4-5 for steady state. If still no effect, discuss dose adjustment or injection technique with your provider.

Does appetite suppression happen faster at higher doses? The timeline of first noticeable effects (day 2-4) is similar across doses, but the intensity is dose-dependent. A patient on 1 mg will feel stronger appetite suppression on day 3 than a patient on 0.25 mg, but both will notice something around the same time window.

Can I feel appetite suppression within 24 hours of injection? Some patients report subtle changes within 24 hours, but this is less common. The 24-48 hour window is when gastric emptying begins slowing measurably, which some patients perceive as early satiety. Clear, consistent appetite suppression usually takes 48-72 hours.

How long does appetite suppression last after each injection? Semaglutide has a 7-day half-life, so appetite suppression lasts through the full week between doses for most patients. Some patients notice reduced effects on days 6-7 (the "trough" before the next injection) and benefit from dose increase or, rarely, twice-weekly dosing.

Does semaglutide stop working for appetite over time? Some patients report slight tolerance (the effect feels less intense after months of use), but objective measures like food intake and weight loss typically continue. True loss of effect is rare and may indicate antibody formation or other medical changes. Discuss with your provider if appetite suppression disappears.

What if I only feel less hungry when I'm nauseous? Nausea and appetite suppression are separate effects. Semaglutide should reduce hunger independent of nausea. If appetite suppression only occurs with nausea, you may need slower dose titration, anti-nausea medication, or a different GLP-1 formulation.

Does injection site affect how fast appetite suppression starts? Injection site (abdomen, thigh, upper arm) doesn't significantly affect absorption speed or appetite suppression timing. All three sites are subcutaneous and produce similar pharmacokinetics. Rotate sites to prevent lipohypertrophy, not to change timing.

Can I speed up appetite suppression by injecting more frequently? No. Semaglutide is dosed weekly because of its long half-life. More frequent injections don't reach steady state faster; they just increase the risk of side effects. Follow your prescribed schedule.

Does food intake on injection day affect appetite suppression timing? No. Semaglutide is injected subcutaneously, not taken orally, so food in your stomach doesn't affect absorption. You can inject before, during, or after meals without changing the timeline.

Will I feel appetite suppression immediately if I switch from Ozempic to Wegovy? If you're already on semaglutide (Ozempic) and switch to Wegovy (same active ingredient, different branding and dosing schedule), you're already at steady state. You won't experience a new "first dose" effect. Appetite suppression continues at the same intensity unless you change doses.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
4. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
5. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
6. Veedfald S et al. The effects of GLP-1 receptor agonists on glucose metabolism, food intake and body weight in patients with type 2 diabetes. Danish Medical Journal. 2016.
7. Sathananthan A et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes Care. 2010.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. Friedrichsen M et al. Response heterogeneity to GLP-1 receptor agonists: potential mechanisms and clinical implications. Lancet Diabetes & Endocrinology. 2022.
11. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024.
12. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes, Obesity and Metabolism. 2016.
13. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
14. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.